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Summary 
In two recent papers, Arenz et al. (2014) and Bischoff et al. (2014) provide structural insights 
into drug-induced, peptide-mediated stalling of the ribosome. 
 
Main Text 
Ribosomes are fast, accurate, and highly processive enzymes. While the ribosome 
translates the vast majority of the proteome efficiently, certain polypeptide sequences stall the 
ribosome either on their own or in combination with a small-molecule (Cruz-Vera et al., 2011). 
Moreover, a number of biological processes have evolved to rely on these peptide-mediated 
stalling events for their functionality, including the induction of erythromycin/macrolide 
resistance (ErmC), regulation of intracellular tryptophan levels (TnaC), and modulation of the 
SecA secretory system (SecM). Over the years, a number of studies have identified many of the 
key residues in both the peptides and ribosome exit tunnel that contribute to pausing. However, 
what has remained unclear is how these interactions affect the structure of the ribosome and in 
particular the peptidyl-transferase center (PTC) to prevent further elongation or termination. Two 
recent papers in Molecular Cell (Arenz et al 2014) and Cell Reports (Bischoff et al 2014) harness 
the power of recent advances in Cryo-EM to address these issues. Both groups report high-
resolution cryo-EM map of peptide-stalled ribosomes that help to shed light on the interactions 
and mechanisms that nascent peptides utilize to mediate these events. 
Building on their previous Cryo-EM studies of the erythromycin-resistance leader 
sequence ErmBL, Arenz and colleauges now address how the related ErmCL, which contains the 
well-conserved IFVI stalling sequence found in many erythromycin-resistance genes, is able to 
modulate interactions between the nascent peptide and exit tunnel residue and how these 
interactions lead to inactivation of the PTC (Arenz et al 2014b) (Arenz et al., 2014). They find 
that in contrast to ErmBL, the ErmCL peptide follows a distinct path in the exit tunnel, bringing 
it much closer to, and even contacting, the bound erythromycin at the bulky cladinose ring of 
erythromycin and F7 of the ErmCL peptide (Fig. 1, top left) (Arenz et al 2014b). This agreed 
well with previous results demonstrating that macrolides without cladinose rings abrogate 
stalling (Vazquez-Laslop et al., 2008). In addition to contacting erythromycin, the C-terminal 
fragment of the peptide interacts with rRNA residues U2506 and U2586 via the conserved IFVI 
motif. They also observed interactions between the N-terminus of the peptide and residues in the 
exit tunnel previously identified by mutagenesis, although the density is too poor to definitively 
assign. With regard to how ErmCL is able to modulate the PTC to prevent further peptide 
elongation, Arenz et al find that a number of residues important for A-site tRNA binding and 
accommodation including U2585, A2602, and U2506 are stabilized by the ErmCL peptide in 
conformations that are distinct from those of the accommodated, non-accommodated, or ErmBL 
structures (Fig. 1, top right). These stabilized conformations appear to be sufficient to preclude 
proper positioning of the incoming A-site tRNA and explain why no bound A-site tRNA is 
observed in their structure. 
In contrast to ErmCL, the TnaC peptide has evolved an entirely different mechanism to 
stall ribosomes. Previous mutagenesis and structural studies had shed light on many of the key 
residues involved in peptide-mediated stalling (Cruz-Vera et al., 2006; Seidelt et al., 2009).  
However, it remained unclear precisely where the tryptophan (Trp) molecule bound to the 
ribosome and how this contributed to inactivation of the PTC and translation blockade (Martinez 
et al., 2014). To decipher this, Bischoff et al, utilized an in vivo purification scheme to isolate a 
large quantity of nearly homogenous TnaC-stalled ribosomes (Bischoff et al 2014). 
Unexpectedly, the resulting Cryo-EM structure revealed not one, but two Trp molecules bound 
in the exit tunnel. Both Trp molecules bind to pockets created by interactions between the 
nascent TnaC peptide and the rRNA (Fig. 1, left middle panel). The first Trp binds between V20 
and I19 of the peptide and U2586 of the ribosome. The second Trp binds in a kink of the peptide 
at N17 and K18, and U2609 and A752 in the 23S rRNA. The second Trp also makes contact 
with A2058 and A2059, residues important for organizing the PTC. Together these interactions 
are sufficient to stabilize A2058, A2059, and A2602 in non-productive positions within the PTC 
and prevent RF2 binding and peptide release (Fig. 1 right middle panel). Yet precisely how these 
interactions conspire to stop translation remains enigmatic. Previous experiments hint at the 
importance of the slowly reacting codon pair (Pro-Stop), however, the precise ordering of the 
conformational changes and tryptophan binding requires future analysis (Cruz-Vera et al., 2006; 
Martinez et al., 2014). 
Two long-standing questions of peptide-mediated stalling have been how the peptides 
specifically interact with the exit tunnel and/or bound small molecules and how these 
interactions lead to a non-functional PTC. Here, Arenz, Bischoff, and colleagues demonstrate 
that both exit tunnel binding and PTC inactivation can occur through a variety of mechanisms. 
For ErmCL, erythromycin binds first, which likely provides the necessary contact between rRNA 
residues in the exit tunnel and the nascent peptide to halt translation. In contrast, the TnaC 
peptide slows translation on its own, potentially allowing sufficient time for the two Trp 
molecules to bind the exit tunnel and completely stall the ribosome (Bischoff et al 2014) (Cruz-
Vera et al., 2006; Martinez et al., 2014). Interestingly, these peptides represent just two examples 
from among a wide variety of known ribosome-stalling peptides. For instance, ErmBL, does not 
rely on the structural contacts between the bound erythromycin and also stabilizes a unique 
conformation of the PTC that allows the A-site tRNA to bind but prevents peptide bond 
formation (Arenz et al., 2014). And while there is not yet a definitive high-resolution structure of 
SecM-mediated stalling, previous Cryo-EM studies suggest that the elongating peptide first 
interacts with the early exit tunnel and then with the constriction point imposed by large subunit 
proteins L4 and L22 (Fig. 1, bottom left and right) (Bhushan et al., 2011). Upon continued 
translation, the peptide gradually becomes more compacted, stabilized, and ultimately stalled. 
Thus, it seems that no two peptides stall the ribosome in the same manner. Moreover, 
biochemical and ribosomal profiling studies have identified a number of peptide motifs that slow 
translation to varying degrees both in vitro and in vivo (Elgamal et al., 2014; Woolstenhulme et 
al., 2013). Whether these effects are mediated solely by interactions between the exit tunnel and 
nascent peptide or in combination with differences in tRNA abundance and reactivity remains 
unclear. However, it will be exciting to explore how proteins have evolved to utilize this 
continuum of translational pausing as a means of modulating gene expression and biological 
regulation.  
 
  
Figure Legends 
Figure 1. Schematic of the interactions between the indicated nascent peptide, ligands and the 
exit tunnel of the ribosome (left). Resulting conformational changes to the peptidyl transferase 
center from these interactions (right).  
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